Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Eligible age
18–75 yrs
Accepts
All genders
Locations
19 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Sponsor: Altimmune, Inc.
You may qualify if…
- ✓ All subjects:
- ✓ No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- ✓ Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- ✓ Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- ✓ Subject agrees to have liver biopsy(ies) as required per protocol
- ✓ Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
- ✓ Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
You may not qualify if…
- ✕ Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- ✕ Uncontrolled T2D or clinically significant persistent hyperglycemia
Where it's recruiting
Dothan
Chandler · Tucson
Little Rock · North Little Rock
Fountain Valley · Fresno · Gardena · Huntington Park …
Englewood
Boca Raton · Bradenton · Miami · Miami Lakes …
Dalton
South Bend
Bastrop · Marrero · Monroe
Laurel
New Bedford
Columbia · Kansas City
Source: ClinicalTrials.gov · NCT07795164 · last updated 2026-11-17